biotech

Latest news and analysis on biotech

Equities

Alzheimer's: No Surprises

It has never been less fun to win on a short. By some counts, Biogen's stock collapse marked the latest failure in over a hundred clinical trials based on the...
Michael Frazis
Frazis Capital

Deep Diving For Asymmetric Upside - New Idea

A lot can be said for understanding what you own, and why you own it. Investors look at stocks like Afterpay, Appen, Altium or A2 Milk and dream of finding such...
ALU
APT
Scott Williams
Fiftyone Capital
Expert Insights

A profound med-tech breakthrough

Catherine Wood, CEO and CIO at ARK Investment Management (ARK), invests on the cutting edge of robotics, energy storage, next-generation internet and blockchain...
Livewire Exclusive
Livewire Markets
Rapid Fire

The Rules of Investing: The Age of Longevity

This week we have our first overseas guest on The Rules of Investing, Jim Mellon. Jim is a billionaire investor, speaker, and co-author of 'Juvenescence: Investing in...
Livewire Exclusive
Livewire Markets

Biotech stocks: the animal spirits are back

Tim Boreham
Tim Boreham
Independent Investment Research

Speculative Bubbles

FMG
Michael Glennon
Michael Glennon
Glennon Capital

A biotech that's been misunderstood

MSB
Livewire Exclusive
Livewire Markets

Lifesciences: Give your portfolio a booster shot

Buy Hold Sell
Livewire Markets

Executive Series 27 Jul 16: Viralytics Ltd (VLA) Managing Director, Malcolm McColl

CommSec
CommSec
Online Stockbroker

A massive market opportunity for Impedimed

IPD
Monash Investors Limited
Monash Investors

Marsico Capital 2016 Global Outlook & Portfolio Positioning

Marsico Capital Management
Marsico Capital Management
Marsico Capital Global Investment insights

The outlook for Healthcare & Biotech's in 2016

Bell Potter
Stockbroker

Merrill Lynch: Own the beneficiaries of disinflation

Livewire News
Livewire News
Livewire

Choosing Between Biotech and Miners

John Robertson
John Robertson
PortfolioDirect

US Markets Strong...... | Happy Friday... | Paradigm Biotech IPO - Keep an eye |

RIO
Niv Dagan
Niv Dagan
Peak Asset Management

Trend alert: Last year saw the biggest overall increase in prescription drug spending in the US since 2003

Livewire Equities
Livewire Equities
Livewire

Yesterday's Australia Biotech Invest 2014 conference in Melbourne rather optimistically considered whether the flight from resources stocks may benefit the...

John Robertson
John Robertson
PortfolioDirect

3 short-term Biotech plays

Livewire Equities
Livewire Equities
Livewire

Bionomics (BNO) - Merck thinks BNC375 is unforgettable, too | Analyst: Stuart Roberts | Rating: Buy TP:$1.10 | Bionomics has secured a new research...

Mathan Somasundaram
Deep Data Analytics

David Merkel from the Aleph Blog says It is wise to avoid the area of the market where issuance is well above average

Livewire News
Livewire News
Livewire
61-80 of 88